Ji Eun Park, Kyung Soo Hong, Sun Ha Choi, Shin Yup Lee, Kyeong-Cheol Shin, Jong Geol Jang, Yong Shik Kwon, Sun Hyo Park, Keum-Ju Choi, Chi Young Jung, Jung Seop Eom, Saerom Kim, Hee Yun Seol, Jehun Kim, Insu Kim, Jin Han Park, Tae Hoon Kim, June Hong Ahn
BACKGROUND: The PACIFIC trial demonstrated survival benefit of durvalumab after concurrent chemoradiotherapy (CCRT) in unresectable stage III non-small-cell lung cancer. Data on the effectiveness and safety of durvalumab in elderly patients is lacking. METHODS: This retrospective study was conducted between September 2017 and September 2022. Progression-free survival (PFS), overall survival (OS), recurrence patterns, first subsequent treatment after recurrence, factors associated with survival outcomes, and adverse events (AEs) were compared...
February 17, 2024: Clinical Lung Cancer